Tell me everything about respiratory diseases with difference clinical

Tell me everything about respiratory diseases with difference clinical features treatment prognosis based on Indian settings

Reading File

Finding Sources

Searching PubMed

respiratory diseases India epidemiology burden

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

COPD India biomass fuel indoor air pollution

Reading File

Finding Sources

Searching PubMed

tuberculosis India treatment outcomes drug resistance

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

This covers the full spectrum of respiratory diseases with India-specific clinical framing. Here are the most important takeaways for the Indian setting:

The "Big Three" by burden:

TB - always exclude first; India has 26% of global burden; NTEP/DOTS is the backbone of management; MDR-TB is rising and requires 2nd/3rd line drugs for 18-24 months (or newer BPaL 6-month oral regimen)
COPD - 55 million patients; biomass fuel is the dominant Indian-specific driver in rural women; spirometry remains under-utilized; LABA/LAMA + smoking/fuel cessation is cornerstone of treatment
Asthma - 30 million affected; urban air pollution and allergen sensitization are key triggers; ICS compliance is the biggest treatment gap in India

What makes Indian respiratory medicine unique:

TB mimics everything - CAP, lung cancer, ILD, and pleural disease
Post-TB sequelae (bronchiectasis, COPD, fibrosis, aspergilloma) create a distinct disease burden not seen in Western practice
Non-smoking COPD from biomass fuel is a uniquely South Asian epidemiological pattern
EGFR mutations are more common in Indian lung adenocarcinoma (~25-30%), making molecular testing essential before starting chemotherapy
Late-stage presentation of lung cancer and ILD remains the norm due to absence of screening programs

This is a shared conversation. Sign in to Orris to start your own chat.